<DOC>
	<DOCNO>NCT02326779</DOCNO>
	<brief_summary>The aim study evaluate survival benefit low-dose aspirin use stage II-III esophageal cancer patient .</brief_summary>
	<brief_title>Low-dose Aspirin Therapy Esophageal Cancer</brief_title>
	<detailed_description>The investigator aim evaluate hypothesis low-dose aspirin improve survival stage II-III esophageal cancer patient , evaluate whether effect influence PIK3CA , KRAS , BRAF mutation COX-2 expression . Eligible participant randomize either aspirin treatment arm ( 100 mg aspirin OD 3 year ) , non-aspirin user arm 1:1 ratio . After randomization , participant receive 3 monthly assessment treatment follow-up .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>1 . Male female subject age 18 year old . 2 . Subjects Stage IIIII histological proven esophageal cancer . 3 . Subjects performance status ( PS ) 01 ECOG performance status 02 . 4 . Subjects must sign approve informed consent prior study procedure . 5 . Subjects adequate bone marrow , hepatic renal function , ) neutrophils ≥ 1.5x109/ L ; platelet ≥ 100x109/L ; hemoglobin ≥ 9g/dL ; b ) Total bilirubin ≤ 2.0 x upper limit normal ; ALT AST ≤ 2.5 x ULN ( ≤ 5 x ULN case liver metastasis ) ; c ) creatinine clearance &gt; 50 ml/min ; 6 . Subjects undergone complete resection primary tumor ; 7 . Subjects life expectancy ≥ 3 month . 8 . Completed standard therapy ( least 3 month chemotherapy ± radiotherapy ) 9 . Within 120 day completion standard therapy ( surgery , chemotherapy ± radiotherapy ) 1 . Subjects haemorrhagic diathesis ( i.e . haemophilia ) . 2 . Subjects prior malignant tumor except esophageal cancer past 5 year . 3 . Subjects document suspected central nervous system metastasis . 4 . Subjects serious , nonhealing wound , ulcer , bone fracture . 5 . Subjects history stroke , coronary arterial disease , angina , vascular disease . 6 . Subjects pregnant , lactating , use adequate contraception . 7 . Subjects know allergy NSAID Aspirin . 8 . Subjects receive antiplatelet agent ( i.e . clopidogrel , ticlopidine ) anticoagulant ( i.e . warfarin , low molecular weight heparin ) . 9 . Subjects receive current long term treatment ( ≥ 1 month ) Aspirin NSAIDs . 10 . Subject unwilling unable comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>aspirin</keyword>
	<keyword>survival</keyword>
</DOC>